There are 2789 resources available
1238P - AUTOMAN: A phase Ib/IIa study of osimertinib combined with anlotinib in EGFRm, treatment-naive advanced NSCLC patients
Presenter: Baohui Han
Session: ePoster Display
1240P - Targeting exon 18 EGFR alterations in non-small cell lung cancer: A patient-level analysis of published data
Presenter: Mehmet Goksu
Session: ePoster Display
1241P - Effects of different brain radiotherapy strategies based on lung-molGPA stratification on the prognosis of patients with brain metastases of EGFR-mutant lung adenocarcinoma
Presenter: Guangchuan Deng
Session: ePoster Display
1242P - Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study
Presenter: Yajun Ji
Session: ePoster Display
1243P - Cumulative incidence and metastatic patterns of relapsed vs de novo stage IV non-small cell lung cancer (NSCLC) characterized by histology and EGFR status
Presenter: Evan Strom
Session: ePoster Display
1244P - Real-world EGFR and T790M testing patterns in patients from Central Eastern Europe with advanced non-small cell lung cancer: Results from a large retrospective study (REFLECT)
Presenter: Mircea Dediu
Session: ePoster Display
1245P - Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance
Presenter: Ruifen Tian
Session: ePoster Display
1246P - A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients
Presenter: Toyoaki Hida
Session: ePoster Display
1247P - Management of infusion-related reactions (IRRs) in patients receiving amivantamab
Presenter: Keunchil Park
Session: ePoster Display